PF4 Promotes Platelet Production and Lung Cancer Growth

Cell Rep. 2016 Nov 8;17(7):1764-1772. doi: 10.1016/j.celrep.2016.10.031.

Abstract

Co-option of host components by solid tumors facilitates cancer progression and can occur in both local tumor microenvironments and remote locations. At present, the signals involved in long-distance communication remain insufficiently understood. Here, we identify platelet factor 4 (PF4, CXCL4) as an endocrine factor whose overexpression in tumors correlates with decreased overall patient survival. Furthermore, engineered PF4 over-production in a Kras-driven lung adenocarcinoma genetic mouse model expanded megakaryopoiesis in bone marrow, augmented platelet accumulation in lungs, and accelerated de novo adenocarcinogenesis. Additionally, anti-platelet treatment controlled mouse lung cancer progression, further suggesting that platelets can modulate the tumor microenvironment to accelerate tumor outgrowth. These findings support PF4 as a cancer-enhancing endocrine signal that controls discrete aspects of bone marrow hematopoiesis and tumor microenvironment and that should be considered as a molecular target in anticancer therapy.

MeSH terms

  • Adenocarcinoma / blood
  • Adenocarcinoma / pathology
  • Adenocarcinoma of Lung
  • Animals
  • Blood Platelets / metabolism*
  • Bone Marrow Cells / metabolism
  • Carcinogenesis / metabolism
  • Carcinogenesis / pathology
  • Cell Lineage
  • Cell Proliferation
  • Disease Progression
  • Humans
  • Lung Neoplasms / blood*
  • Lung Neoplasms / pathology*
  • Megakaryocytes / metabolism
  • Mice
  • Platelet Factor 4 / metabolism*
  • Proto-Oncogene Proteins p21(ras) / metabolism
  • Survival Analysis

Substances

  • KRAS protein, human
  • Platelet Factor 4
  • Proto-Oncogene Proteins p21(ras)